Elimnion
Book a call

For owners of clinical-stage drug assets

Phase 1 or 2 data, but no budget for Phase 3? I find the licensing partner.

For assets stuck before a pivotal trial, and programmes shelved for business reasons. I build the case a partner needs to see, and take it to the companies with a reason to say yes.

Book a 30-minute call How it works
  • Paid on a signed deal
  • You approve every approach
Asset dossierWhat you receive
Human data
Trials, endpoints and outcomes, each linked to its source
Why it stalled
The reason, and what would change it
Rights
Owner, licence chain and patent expiry
Partners
Who fits, and what they have done before
Partners receive the same document, so you see exactly what they see.

Approach

Why the asset stalled decides who to approach.

No budget for Phase 3

A partner funds the pivotal trial in return for rights. Option and milestone-based deals lower what they pay up front.

The owner's strategy moved on

A smaller, focused company for which the asset is core, not a side project.

Large pharma already passed

Specialty pharma, regional licensees and companies that licensed something similar decide on different grounds.

How it works

Four steps, with a clear exit after each.

  1. Intro call

    Thirty minutes on the asset and what you want. Public information is enough.

  2. Mutual NDA

    Signed before you share anything specific.

  3. Assessment

    The dossier, a rights check and a written go or no-go.

  4. Partner process

    Outreach, first calls and written reports. You approve every name.

Looking to in-license an asset?

Send your therapy area, stage and deal type. When an asset I work on matches, you hear about it directly.

Send your criteria

Questions

What asset owners ask first.

What does it cost?
The intro call is free. Early engagements are paid by a success fee when a deal is signed, agreed in writing before any outreach. Larger mandates can add a fixed fee, also agreed up front.
What if no deal comes out of it?
You pay no success fee, and you keep the dossier and a record of every reply.
Large pharma already passed. Is it worth another try?
Sometimes. Smaller and regional buyers decide on different grounds. If the data itself is the problem, I tell you at the assessment.
How is confidential information handled?
A mutual NDA comes first. Nothing confidential goes to a third party, including AI services, without your written approval, and your material is returned or deleted at the end.
What is not a fit?
Preclinical-only programmes, approved drugs, and raising investment. I work on licensing and partnering only.

About

One person, accountable for the work.

Elimnion is run by Panos Tsampanis, an ML engineer in drug discovery with a background in pharmaceutical sciences. I read the clinical data myself and build the tools that search trial registries, filings and deal records for the right partners.

  • Based inBrussels, Belgium
  • LanguagesEnglish, Dutch
  • RegisteredKBO 0786.741.660

Tell me about the asset.

In thirty minutes you will know whether a partner process makes sense.

Book a 30-minute call

tsampanis.panagiotis@gmail.com